Paper30836166
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.
Pasalic D and 13 others. Int J Radiat Oncol Biol Phys, 2019. Cited by 83 papers, by iCite.
Cite this record
ConductScience Library. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Papers, record 30836166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30836166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Dose Fractionation, Radiation | Major topic |
| Prostatic Neoplasms | Major topic |
| Salvage Therapy | Major topic |
| Aged | |
| Aged, 80 and over | |
| Follow-Up Studies | |
| Humans | |
| Kallikreins | |
| Male | |
| Middle Aged | |
| Neoplasm Grading | |
| Neoplasms, Second Primary | |
| Prostate-Specific Antigen | |
| Time Factors | |
| Treatment Failure | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 CA006294 | NCI NIH HHS | United States | P01CA006294 | PubMed and NIH | NIH RePORTER |
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 31204661 | Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. | https://conductscience.org/library/papers/31204661 |
Source PubMed
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21147514 | 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. | Int J Radiat Oncol Biol Phys | 2011 | https://conductscience.org/library/papers/21147514 | PubMed |
| 2 | 8119066 | Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]. | Control Clin Trials | 1993 | https://conductscience.org/library/papers/8119066 | PubMed |
| 3 | 24485765 | Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. | Radiother Oncol | 2014 | https://conductscience.org/library/papers/24485765 | PubMed |
| 4 | 24725694 | Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer. | Int J Radiat Oncol Biol Phys | 2014 | https://conductscience.org/library/papers/24725694 | PubMed |
| 5 | 24581940 | Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24581940 | PubMed |
| 6 | 18926640 | A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. | Cancer Treat Rev | 2009 | https://conductscience.org/library/papers/18926640 | PubMed |
| 7 | 27626136 | 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27626136 | PubMed |
| 8 | 24373762 | A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. | Brachytherapy | 2014 | https://conductscience.org/library/papers/24373762 | PubMed |
| 9 | 22318190 | [Quality of life after biochemical recurrence in patients with prostate cancer. How and how long do patients live after biochemical recurrence?]. | Arch Esp Urol | 2012 | https://conductscience.org/library/papers/22318190 | PubMed |
| 10 | 9169810 | Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. | Int J Radiat Oncol Biol Phys | 1997 | https://conductscience.org/library/papers/9169810 | PubMed |
| 11 | 29904742 | Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. | Adv Radiat Oncol | 2018 | https://conductscience.org/library/papers/29904742 | PubMed |
| 12 | 15990025 | The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. | Int J Radiat Oncol Biol Phys | 2005 | https://conductscience.org/library/papers/15990025 | PubMed |
| 13 | 29543933 | Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/29543933 | PubMed |
| 14 | 22889401 | Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. | BJU Int | 2012 | https://conductscience.org/library/papers/22889401 | PubMed |
| 15 | 11099319 | Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. | J Clin Oncol | 2000 | https://conductscience.org/library/papers/11099319 | PubMed |
| 16 | 16798415 | Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. | Int J Radiat Oncol Biol Phys | 2006 | https://conductscience.org/library/papers/16798415 | PubMed |
| 17 | 10974469 | External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. | Int J Radiat Oncol Biol Phys | 2000 | https://conductscience.org/library/papers/10974469 | PubMed |
| 18 | 20124169 | Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20124169 | PubMed |
| 19 | 12504054 | How low is the alpha/beta ratio for prostate cancer? | Int J Radiat Oncol Biol Phys | 2003 | https://conductscience.org/library/papers/12504054 | PubMed |
| 20 | 25139441 | Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis. | Urol Int | 2014 | https://conductscience.org/library/papers/25139441 | PubMed |
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42878878 | EQUIPOISE: EQUivalence In Prostate cancer treatment: surgery Or radiotherapy? An Intention-to-treat Survival analysis from real-world Evidence. | World J Urol | 2026 | https://conductscience.org/library/papers/42878878 | PubMed |
| 42728103 | Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities. | J Nucl Med | 2026 | https://conductscience.org/library/papers/42728103 | PubMed |
| 42232852 | Polish Brachytherapy Society clinical recommendations and expert consensus on radical high-dose-rate brachytherapy for prostate cancer. | J Contemp Brachytherapy | 2026 | https://conductscience.org/library/papers/42232852 | PubMed |
| 42205730 | Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer. | Clin Transl Radiat Oncol | 2026 | https://conductscience.org/library/papers/42205730 | PubMed |
| 42028292 | Particle Therapy Co-Operative Group Consensus Statement on Reirradiation With Proton Therapy for Prostate Cancer. | Int J Part Ther | 2026 | https://conductscience.org/library/papers/42028292 | PubMed |
| 41809561 | Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity. | Adv Radiat Oncol | 2026 | https://conductscience.org/library/papers/41809561 | PubMed |
| 41634712 | Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters. | Radiat Oncol | 2026 | https://conductscience.org/library/papers/41634712 | PubMed |
| 41590513 | Treatment-Free Survival and the Pattern of Follow-Up Treatments After Curative Prostate Cancer Treatment, a Real-World Analysis of Big Data from Electronic Health Records from a Tertiary Center. | J Pers Med | 2026 | https://conductscience.org/library/papers/41590513 | PubMed |
| 41583333 | Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation Therapy. | Adv Radiat Oncol | 2026 | https://conductscience.org/library/papers/41583333 | PubMed |
| 41541754 | Dosimetric Feasibility of Dose-Painting Radiation Therapy for Targeting Hypoxia in Prostate Cancer on a Novel Ring Gantry Radiation Therapy System. | Adv Radiat Oncol | 2026 | https://conductscience.org/library/papers/41541754 | PubMed |
| 40564029 | Long-Term Outcomes After High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy in Very High-Risk Prostate Cancer: A 24-Year Follow-Up. | Biomedicines | 2025 | https://conductscience.org/library/papers/40564029 | PubMed |
| 40558303 | Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer. | Curr Oncol | 2025 | https://conductscience.org/library/papers/40558303 | PubMed |
| 40558264 | Can Deep Learning-Based Auto-Contouring Software Achieve Accurate Pelvic Volume Delineation in Volumetric Image-Guided Radiotherapy for Prostate Cancer? A Preliminary Multicentric Analysis. | Curr Oncol | 2025 | https://conductscience.org/library/papers/40558264 | PubMed |
| 40518535 | Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose. | Radiat Oncol | 2025 | https://conductscience.org/library/papers/40518535 | PubMed |
| 39901943 | Fully automatic reconstruction of prostate high-dose-rate brachytherapy interstitial needles using two-phase deep learning-based segmentation and object tracking algorithms. | Clin Transl Radiat Oncol | 2025 | https://conductscience.org/library/papers/39901943 | PubMed |
| 39855400 | The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic "Microboost". | Int J Radiat Oncol Biol Phys | 2025 | https://conductscience.org/library/papers/39855400 | PubMed |
| 39849412 | Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan. | BMC Urol | 2025 | https://conductscience.org/library/papers/39849412 | PubMed |
| 39802319 | The clinical application of in vivo dosimetry for gynaecological brachytherapy: A scoping review. | Tech Innov Patient Support Radiat Oncol | 2025 | https://conductscience.org/library/papers/39802319 | PubMed |
| 39628817 | Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy. | J Contemp Brachytherapy | 2024 | https://conductscience.org/library/papers/39628817 | PubMed |
| 39165591 | Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-Linac in localized prostate cancer. | Rep Pract Oncol Radiother | 2024 | https://conductscience.org/library/papers/39165591 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KLK3 | 354 | PubTator's text mining | https://conductscience.org/library/genes/354 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30836166
GET https://conductscience.org/api/papers/v1/30836166/references?page=2